

2016-01-18

## Cell laboratory at Japanese university orders 3<sup>rd</sup> HoloMonitor

One of the cell laboratories at Kyushu University in Japan has ordered two HoloMonitor® instruments to complement the instrument previously purchased by the laboratory. The university is one of the seven imperial universities which today form Japan's prestigious national universities. An additional four HoloMonitor M4.5 instruments have recently been ordered by customers in the UK, Israel, Australia and Singapore. The total retail price of the ordered units amounts to €144 000.

*"The follow-up order from Kyushu University once again confirms the scientific value of our HoloMonitor-technology. Furthermore, the order indicates that cell laboratories will require several instruments to accommodate the expanding research needs created by HoloMonitor technology. The laboratory at Kyushu University will become the 9<sup>th</sup> cell laboratory with several HoloMonitor instruments in operation. Independent market reports estimate the number of cell laboratories in the world to approximately 120 000",* said CEO Peter Egelberg.

### Links

- The Market for Cell-Based Assays – <http://www.gene2drug.com/images/IMI-The-Market-for-Cell-Based-Assays-Report-Brochure-15-011-Final.pdf>

### For additional information, please contact:

Peter Egelberg, CEO

Tel: +46 703 19 42 74

E-mail: [peter.egelberg@phiab.se](mailto:peter.egelberg@phiab.se)

Web: [www.phiab.se](http://www.phiab.se)

---

*Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.*